{"id":24049,"date":"2025-02-26T09:20:02","date_gmt":"2025-02-26T14:20:02","guid":{"rendered":"https:\/\/medicarereport.org\/?p=24049"},"modified":"2025-02-26T09:20:03","modified_gmt":"2025-02-26T14:20:03","slug":"did-an-alzheimers-drug-give-sue-and-ken-bell-more-time-maybe","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=24049","title":{"rendered":"Did an Alzheimer&#8217;s drug give Sue and Ken Bell more time? Maybe"},"content":{"rendered":"\n<p>(By Jon Hamilton for NPR)<\/p>\n\n\n\n<p>In 2020, Sue Bell became one of the first Alzheimer&#8217;s patients in the U.S. to receive the drug now marketed as Leqembi.<\/p>\n\n\n\n<p>Four years later, she and her husband, Ken, halted the treatment. Sue&#8217;s Alzheimer&#8217;s had reached the point where her taking the drug no longer made sense.  Continue reading <a href=\"https:\/\/www.npr.org\/sections\/shots-health-news\/2025\/02\/26\/nx-s1-5300930\/did-an-alzheimers-drug-give-sue-and-ken-bell-more-time-maybe\" data-type=\"link\" data-id=\"https:\/\/www.npr.org\/sections\/shots-health-news\/2025\/02\/26\/nx-s1-5300930\/did-an-alzheimers-drug-give-sue-and-ken-bell-more-time-maybe\">here&#8230;<\/a><\/p>\n\n\n\n<p><img loading=\"lazy\" decoding=\"async\" width=\"150\" height=\"54\" class=\"wp-image-3902\" style=\"width: 150px;\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/08\/NPR-logo.png\" alt=\"\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/08\/NPR-logo.png 152w, https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/08\/NPR-logo-150x55.png 150w\" sizes=\"auto, (max-width: 150px) 100vw, 150px\" \/><\/p>\n\n\n\n<p class=\"has-small-font-size\"><strong>Notice:<\/strong>\u00a0The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>(By Jon Hamilton for NPR) In 2020, Sue Bell became one of the first Alzheimer&#8217;s patients in the U.S. to<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[18,26,15],"tags":[116,769],"class_list":["post-24049","post","type-post","status-publish","format-standard","hentry","category-aging","category-alzheimersdementia","category-part-dprescription-drugs","tag-alzheimers-disease","tag-leqembi"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/24049","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=24049"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/24049\/revisions"}],"predecessor-version":[{"id":24050,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/24049\/revisions\/24050"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=24049"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=24049"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=24049"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}